Login to Your Account



$900M Asthma Partnership

AstraZeneca, MAP Enter Deal for Reformulated Asthma Drug

By Catherine Hollingsworth


Monday, December 22, 2008
In its first deal with a major drugmaker, MAP Pharmaceuticals Inc. has joined with London-based AstraZeneca to develop and commercialize a nebulized form of budesonide, a potential treatment for pediatric asthma that could work more quickly and at a lower dose than AstraZeneca's blockbuster asthma drug Pulmicort. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription